Research Reports | Market Assessment
$24,750.00
April 2021

Progressive Supranuclear Palsy – Executive Insights – Progressive Supranuclear Palsy | Executive Insights (US/EU5/China)

Table of contents

  • Progressive Supranuclear Palsy - Executive Insights - Progressive Supranuclear Palsyu00a0| Executive Insights (US/EU5/China)
    • Progressive Supranuclear Palsyu00a0 | Executive Insights | US/EU5/China | 2021
Ruchita Kumar, Ph.D.
Ruchita Kumar, Ph.D.

Ruchita Kumar, M.Pharm., Ph.D., is a manager on the CNS/Ophthalmology Disorders team at Clarivate. Her specialties are migraine and Alzheimer’s disease. She has worked on a variety of opportunity assessment and market intelligence projects involving the preparation of disease narratives, epi-based forecasts, and building brand performance reports across different therapy areas. She holds a Ph.D. in the design and development of modified-release dosing forms of antidiabetic drugs from the University Institute of Pharmaceutical Sciences at Panjab University in Chandigarh, India.

Anamika Ghosh, Ph.D.
Anamika Ghosh, Ph.D.

Anamika Ghosh, M.Sc., Ph.D., is a manager on the Oncology team at Clarivate. She has expertise in various solid and hematological malignancies and immune-oncology drug classes, such as immune checkpoint inhibitors and CAR T-cell therapies. As a Ph.D. and postdoctoral fellow at the International Centre for Genetic Engineering and Biotechnology (ICGEB), Dr. Ghosh studied host-pathogen interactions during Mycobacterium tuberculosis and Dengue virus infections. She received her Ph.D. in life sciences from ICGEB and an M.Sc. in biomedical sciences from the University of Delhi.

Buy report Login to access report
Back to all Market Assessment reports
Buy report
Login to access report

launch Related Market Assessment Reports